Proteasome Maturation Protein (pomp) Is Associated With Proteasome Inhibitor Resistance In Myeloma, and Its Suppression Enhances The Activity Of Bortezomib and Carfilzomib

被引：1
|
作者：
Li, Bingzong
Wang, Hua
Orlowski, Robert Z.
机构：
来源：
BLOOD | 2013年 / 122卷 / 21期
关键词：
D O I：
10.1182/blood.V122.21.280.280
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
280
引用
收藏
页数：2
相关论文
共 50 条
  • [1] PR671, the first proteasome inhibitor that selectively inhibits the bortezomib/carfilzomib insensitive β2 proteasome subunits, overcomes bortezomib/carfilzomib resistance in myeloma cells in vitro
    Driessen, C.
    Kraus, M.
    van der Linden, W. A.
    Bader, J.
    Overkleeft, H. S.
    [J]. ONKOLOGIE, 2012, 35 : 176 - 176
  • [2] Nelfinavir augments proteasome inhibition by bortezomib in myeloma cells and overcomes bortezomib and carfilzomib resistance
    Kraus, M.
    Bader, J.
    Overkleeft, H.
    Driessen, C.
    [J]. BLOOD CANCER JOURNAL, 2013, 3 : e103 - e103
  • [3] The proteasome maturation protein POMP increases proteasome assembly and activity in psoriatic lesional skin
    Zieba, Barbara A.
    Henry, Laurent
    Lacroix, Matthieu
    Jemaa, Mohamed
    Lavabre-Bertrand, Thierry
    Meunier, Laurent
    Coux, Olivier
    Stoebner, Pierre-Emmanuel
    [J]. JOURNAL OF DERMATOLOGICAL SCIENCE, 2017, 88 (01) : 10 - 19
  • [4] Nelfinavir augments proteasome inhibition by bortezomib in myeloma cells and overcomes bortezomib and carfilzomib resistance
    M Kraus
    J Bader
    H Overkleeft
    C Driessen
    [J]. Blood Cancer Journal, 2013, 3 : e103 - e103
  • [5] The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells
    Kraus, Marianne
    Bader, Juergen
    Geurink, Paul P.
    Weyburne, Emily S.
    Mirabella, Anne C.
    Silzle, Tobias
    Shabaneh, Tamer B.
    van der Linden, Wouter A.
    de Bruin, Gerjan
    Haile, Sarah R.
    van Rooden, Eva
    Appenzeller, Christina
    Li, Nan
    Kisselev, Alexei F.
    Overkleeft, Herman
    Driessen, Christoph
    [J]. HAEMATOLOGICA, 2015, 100 (10) : 1350 - 1360
  • [6] Sustained proteasome inhibition by carfilzomib, a selective proteasome inhibitor, enhances anti-tumor activity
    Aujay, Monette
    Demo, Susan
    Jiang, Jing
    Kirk, Christopher
    Parlati, Francesco
    Suzuki, Erika
    Woo, Tina
    Bennett, Mark
    [J]. CANCER RESEARCH, 2009, 69
  • [7] The proteasome inhibitor CEP-18770 enhances the anti-myeloma activity of bortezomib and melphalan
    Sanchez, Eric
    Li, Mingjie
    Steinberg, Jeffrey A.
    Wang, Cathy
    Shen, Jing
    Bonavida, Benjamin
    Li, Zhi-Wei
    Chen, Haiming
    Berenson, James R.
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2010, 148 (04) : 569 - 581
  • [8] Dyclonine enhances the cytotoxic effect of proteasome inhibitor bortezomib in multiple myeloma cells
    Ju, Donghong
    Xie, Youming
    [J]. MOLECULAR MEDICINE REPORTS, 2014, 10 (05) : 2609 - 2612
  • [9] Pharmacogenomic Study of Carfilzomib in Relapsed/Refractory Multiple Myeloma Suggests That Carfilzomib Is a More Potent Proteasome Inhibitor Than Bortezomib
    Zhang, Qing
    Heuck, Christoph
    Qiang, Ya-Wei
    van Rhee, Frits
    Waheed, Sarah
    Bailey, Clyde
    Panozzo, Susan B.
    Epstein, Joshua
    Barlogie, Bart
    Usmani, Saad Z.
    [J]. BLOOD, 2012, 120 (21)
  • [10] Combination Therapy with Bortezomib or Carfilzomib and Selinexor Induces Nuclear Localization of Ikba and Overcomes Acquired Proteasome Inhibitor Resistance in Human Multiple Myeloma
    Turner, Joel G.
    Kashyap, Trinayan
    Dawson, Jana L.
    Gomez, Juan A.
    Bauer, Alexis
    Grant, Steven
    Dai, Yun
    Shain, Kenneth H.
    Meads, Mark B.
    Landesman, Yosef
    Sullivan, Daniel M.
    [J]. BLOOD, 2016, 128 (22)
12345